Is SLNO or FEMY more profitable?

Soleno Therapeutics has a net margin of 33.70% compared to Femasys' net margin of -521.97%. Soleno Therapeutics' return on equity of 22.85% beat Femasys' return on equity. Company Net Margins Return on Equity Return on Assets Soleno Therapeutics 33.70% 22.85% 18.25% Femasys -521.97% -258.08% -73.72%

Do analysts prefer FEMY or BDMD?

Femasys presently has a consensus price target of $106.67, suggesting a potential upside of 2,775.11%. Given Femasys' stronger consensus rating and higher possible upside, research analysts plainly believe Femasys is more favorable than Baird Medical Investment. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Femasys 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50 Baird Medical Investment 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher earnings & valuation, FEMY or BDMD?

Baird Medical Investment has higher revenue and earnings than Femasys. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Femasys $2.38M 4.71 -$18.63M -$5.40 N/A Baird Medical Investment $22.54M 1.85 N/A N/A N/A

Do analysts prefer FEMY or IINN?

Femasys currently has a consensus target price of $106.67, suggesting a potential upside of 2,775.11%. Given Femasys' stronger consensus rating and higher probable upside, analysts clearly believe Femasys is more favorable than Inspira Technologies OXY B.H.N.. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Femasys 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50 Inspira Technologies OXY B.H.N. 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger earnings and valuation, FEMY or IINN?

Inspira Technologies OXY B.H.N. has lower revenue, but higher earnings than Femasys. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Femasys $2.38M 4.71 -$18.63M -$5.40 N/A Inspira Technologies OXY B.H.N. $289K 109.60 -$13.22M N/A N/A

Does the media prefer FEMY or IINN?

In the previous week, Femasys had 1 more articles in the media than Inspira Technologies OXY B.H.N.. MarketBeat recorded 2 mentions for Femasys and 1 mentions for Inspira Technologies OXY B.H.N.. Femasys' average media sentiment score of 0.94 beat Inspira Technologies OXY B.H.N.'s score of 0.00 indicating that Femasys is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Femasys 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Inspira Technologies OXY B.H.N. 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend FEMY or QTI?

Femasys currently has a consensus price target of $106.67, suggesting a potential upside of 2,775.11%. Given Femasys' stronger consensus rating and higher probable upside, equities research analysts clearly believe Femasys is more favorable than QT Imaging. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Femasys 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50 QT Imaging 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is FEMY or QTI more profitable?

QT Imaging has a net margin of -58.93% compared to Femasys' net margin of -521.97%. Femasys' return on equity of -258.08% beat QT Imaging's return on equity. Company Net Margins Return on Equity Return on Assets Femasys -521.97% -258.08% -73.72% QT Imaging -58.93% -4,220.38% -51.77%

Do analysts rate QTEX or FEMY?

Femasys has a consensus price target of $106.67, indicating a potential upside of 2,775.11%. Given Femasys' stronger consensus rating and higher possible upside, analysts clearly believe Femasys is more favorable than Inspira Technologies OXY B.H.N.. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Inspira Technologies OXY B.H.N. 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Femasys 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50

Which has stronger earnings & valuation, QTEX or FEMY?

Inspira Technologies OXY B.H.N. has higher earnings, but lower revenue than Femasys. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Inspira Technologies OXY B.H.N. $290K 109.23 -$13.22M N/A N/A Femasys $2.38M 4.71 -$18.63M -$5.40 N/A

Does the media favor QTEX or FEMY?

In the previous week, Inspira Technologies OXY B.H.N. had 2 more articles in the media than Femasys. MarketBeat recorded 4 mentions for Inspira Technologies OXY B.H.N. and 2 mentions for Femasys. Femasys' average media sentiment score of 0.94 beat Inspira Technologies OXY B.H.N.'s score of 0.23 indicating that Femasys is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Inspira Technologies OXY B.H.N. 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Femasys 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Femasys (FEMY) Competitors

$3.71 -0.08 (-2.11%)

Closing price 07/24/2026 04:00 PM Eastern

Extended Trading

$3.74 +0.03 (+0.81%)

As of 07/24/2026 07:34 PM Eastern

Compare

FEMY vs. SLNO, BDMD, IINN, QTI, and QTEX

Should you buy Femasys stock or one of its competitors? MarketBeat compares Femasys with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Femasys include Soleno Therapeutics (SLNO), Baird Medical Investment (BDMD), Inspira Technologies OXY B.H.N. (IINN), QT Imaging (QTI), and Inspira Technologies OXY B.H.N. (QTEX). These companies are all part of the "medical equipment" industry.

How does Femasys compare to Soleno Therapeutics?

Soleno Therapeutics (NASDAQ:SLNO) and Femasys (NASDAQ:FEMY) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their valuation, risk, earnings, profitability, analyst recommendations, institutional ownership, media sentiment and dividends.

Soleno Therapeutics has higher revenue and earnings than Femasys. Femasys is trading at a lower price-to-earnings ratio than Soleno Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Soleno Therapeutics	$285.01M	9.69	$20.89M	$1.77	29.95
Femasys	$2.38M	4.71	-$18.63M	-$5.40	N/A

In the previous week, Femasys had 2 more articles in the media than Soleno Therapeutics. MarketBeat recorded 2 mentions for Femasys and 0 mentions for Soleno Therapeutics. Soleno Therapeutics' average media sentiment score of 0.94 equaled Femasys'average media sentiment score.

Company	Overall Sentiment
Soleno Therapeutics	Positive
Femasys	Positive

97.4% of Soleno Therapeutics shares are owned by institutional investors. Comparatively, 65.3% of Femasys shares are owned by institutional investors. 6.4% of Soleno Therapeutics shares are owned by insiders. Comparatively, 7.8% of Femasys shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Soleno Therapeutics has a net margin of 33.70% compared to Femasys' net margin of -521.97%. Soleno Therapeutics' return on equity of 22.85% beat Femasys' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Soleno Therapeutics	33.70%	22.85%	18.25%
Femasys	-521.97%	-258.08%	-73.72%

Soleno Therapeutics currently has a consensus target price of $76.67, suggesting a potential upside of 44.63%. Femasys has a consensus target price of $106.67, suggesting a potential upside of 2,775.11%. Given Femasys' stronger consensus rating and higher probable upside, analysts clearly believe Femasys is more favorable than Soleno Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Soleno Therapeutics	2 Sell rating(s)	8 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.08
Femasys	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

Soleno Therapeutics has a beta of -2.22, meaning that its stock price is 322% less volatile than the broader market. Comparatively, Femasys has a beta of -2.13, meaning that its stock price is 313% less volatile than the broader market.

Summary

Soleno Therapeutics beats Femasys on 9 of the 14 factors compared between the two stocks.

How does Femasys compare to Baird Medical Investment?

Femasys (NASDAQ:FEMY) and Baird Medical Investment (NASDAQ:BDMD) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, valuation, profitability, media sentiment, earnings, dividends, analyst recommendations and institutional ownership.

Baird Medical Investment has higher revenue and earnings than Femasys.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Femasys	$2.38M	4.71	-$18.63M	-$5.40	N/A
Baird Medical Investment	$22.54M	1.85	N/A	N/A	N/A

In the previous week, Femasys and Femasys both had 2 articles in the media. Baird Medical Investment's average media sentiment score of 1.43 beat Femasys' score of 0.94 indicating that Baird Medical Investment is being referred to more favorably in the news media.

Company	Overall Sentiment
Femasys	Positive
Baird Medical Investment	Positive

Femasys presently has a consensus price target of $106.67, suggesting a potential upside of 2,775.11%. Given Femasys' stronger consensus rating and higher possible upside, research analysts plainly believe Femasys is more favorable than Baird Medical Investment.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Femasys	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Baird Medical Investment	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Baird Medical Investment has a net margin of 0.00% compared to Femasys' net margin of -521.97%. Baird Medical Investment's return on equity of 0.00% beat Femasys' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Femasys	-521.97%	-258.08%	-73.72%
Baird Medical Investment	N/A	N/A	N/A

Femasys has a beta of -2.13, meaning that its share price is 313% less volatile than the broader market. Comparatively, Baird Medical Investment has a beta of -1.17, meaning that its share price is 217% less volatile than the broader market.

65.3% of Femasys shares are owned by institutional investors. Comparatively, 19.8% of Baird Medical Investment shares are owned by institutional investors. 7.8% of Femasys shares are owned by insiders. Comparatively, 78.9% of Baird Medical Investment shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Baird Medical Investment beats Femasys on 7 of the 12 factors compared between the two stocks.

How does Femasys compare to Inspira Technologies OXY B.H.N.?

Femasys (NASDAQ:FEMY) and Inspira Technologies OXY B.H.N. (NASDAQ:IINN) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, profitability, earnings, analyst recommendations, valuation, institutional ownership, media sentiment and risk.

Inspira Technologies OXY B.H.N. has a net margin of 0.00% compared to Femasys' net margin of -521.97%. Inspira Technologies OXY B.H.N.'s return on equity of 0.00% beat Femasys' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Femasys	-521.97%	-258.08%	-73.72%
Inspira Technologies OXY B.H.N.	N/A	N/A	N/A

65.3% of Femasys shares are owned by institutional investors. Comparatively, 12.7% of Inspira Technologies OXY B.H.N. shares are owned by institutional investors. 7.8% of Femasys shares are owned by company insiders. Comparatively, 29.4% of Inspira Technologies OXY B.H.N. shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Inspira Technologies OXY B.H.N. has lower revenue, but higher earnings than Femasys.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Femasys	$2.38M	4.71	-$18.63M	-$5.40	N/A
Inspira Technologies OXY B.H.N.	$289K	109.60	-$13.22M	N/A	N/A

Femasys currently has a consensus target price of $106.67, suggesting a potential upside of 2,775.11%. Given Femasys' stronger consensus rating and higher probable upside, analysts clearly believe Femasys is more favorable than Inspira Technologies OXY B.H.N..

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Femasys	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Inspira Technologies OXY B.H.N.	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Femasys had 1 more articles in the media than Inspira Technologies OXY B.H.N.. MarketBeat recorded 2 mentions for Femasys and 1 mentions for Inspira Technologies OXY B.H.N.. Femasys' average media sentiment score of 0.94 beat Inspira Technologies OXY B.H.N.'s score of 0.00 indicating that Femasys is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Femasys	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Inspira Technologies OXY B.H.N.	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Femasys has a beta of -2.13, meaning that its share price is 313% less volatile than the broader market. Comparatively, Inspira Technologies OXY B.H.N. has a beta of 2.16, meaning that its share price is 116% more volatile than the broader market.

Summary

Femasys and Inspira Technologies OXY B.H.N. tied by winning 7 of the 14 factors compared between the two stocks.

How does Femasys compare to QT Imaging?

Femasys (NASDAQ:FEMY) and QT Imaging (NASDAQ:QTI) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, media sentiment, dividends, institutional ownership and earnings.

QT Imaging has a net margin of -58.93% compared to Femasys' net margin of -521.97%. Femasys' return on equity of -258.08% beat QT Imaging's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Femasys	-521.97%	-258.08%	-73.72%
QT Imaging	-58.93%	-4,220.38%	-51.77%

Femasys has a beta of -2.13, indicating that its stock price is 313% less volatile than the broader market. Comparatively, QT Imaging has a beta of -0.04, indicating that its stock price is 104% less volatile than the broader market.

65.3% of Femasys shares are owned by institutional investors. Comparatively, 24.2% of QT Imaging shares are owned by institutional investors. 7.8% of Femasys shares are owned by company insiders. Comparatively, 25.4% of QT Imaging shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Femasys has higher earnings, but lower revenue than QT Imaging. QT Imaging is trading at a lower price-to-earnings ratio than Femasys, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Femasys	$2.38M	4.71	-$18.63M	-$5.40	N/A
QT Imaging	$22.66M	1.68	-$21.08M	-$1.24	N/A

Femasys currently has a consensus price target of $106.67, suggesting a potential upside of 2,775.11%. Given Femasys' stronger consensus rating and higher probable upside, equities research analysts clearly believe Femasys is more favorable than QT Imaging.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Femasys	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
QT Imaging	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Femasys had 1 more articles in the media than QT Imaging. MarketBeat recorded 2 mentions for Femasys and 1 mentions for QT Imaging. QT Imaging's average media sentiment score of 1.91 beat Femasys' score of 0.94 indicating that QT Imaging is being referred to more favorably in the news media.

Company	Overall Sentiment
Femasys	Positive
QT Imaging	Very Positive

Summary

Femasys beats QT Imaging on 9 of the 16 factors compared between the two stocks.

How does Femasys compare to Inspira Technologies OXY B.H.N.?

Inspira Technologies OXY B.H.N. (NASDAQ:QTEX) and Femasys (NASDAQ:FEMY) are both small-cap medical equipment companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, media sentiment, valuation, profitability, analyst recommendations, institutional ownership, risk and dividends.

12.7% of Inspira Technologies OXY B.H.N. shares are held by institutional investors. Comparatively, 65.3% of Femasys shares are held by institutional investors. 29.4% of Inspira Technologies OXY B.H.N. shares are held by insiders. Comparatively, 7.8% of Femasys shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, Inspira Technologies OXY B.H.N. had 2 more articles in the media than Femasys. MarketBeat recorded 4 mentions for Inspira Technologies OXY B.H.N. and 2 mentions for Femasys. Femasys' average media sentiment score of 0.94 beat Inspira Technologies OXY B.H.N.'s score of 0.23 indicating that Femasys is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Inspira Technologies OXY B.H.N.	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Femasys	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Inspira Technologies OXY B.H.N. has higher earnings, but lower revenue than Femasys.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Inspira Technologies OXY B.H.N.	$290K	109.23	-$13.22M	N/A	N/A
Femasys	$2.38M	4.71	-$18.63M	-$5.40	N/A

Femasys has a consensus price target of $106.67, indicating a potential upside of 2,775.11%. Given Femasys' stronger consensus rating and higher possible upside, analysts clearly believe Femasys is more favorable than Inspira Technologies OXY B.H.N..

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Inspira Technologies OXY B.H.N.	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Femasys	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

Inspira Technologies OXY B.H.N. has a net margin of 0.00% compared to Femasys' net margin of -521.97%. Inspira Technologies OXY B.H.N.'s return on equity of 0.00% beat Femasys' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Inspira Technologies OXY B.H.N.	N/A	N/A	N/A
Femasys	-521.97%	-258.08%	-73.72%

Inspira Technologies OXY B.H.N. has a beta of 4.2, indicating that its stock price is 320% more volatile than the broader market. Comparatively, Femasys has a beta of -2.13, indicating that its stock price is 313% less volatile than the broader market.

Summary

Inspira Technologies OXY B.H.N. beats Femasys on 8 of the 14 factors compared between the two stocks.

Get Femasys News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding FEMY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

FEMY vs. The Competition

Export

Metric	Femasys	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$11.20M	$3.67B	$6.87B	$12.26B
Dividend Yield	N/A	2.19%	2.67%	9.79%
P/E Ratio	-0.69	21.29	27.11	23.64
Price / Sales	4.71	170.12	517.09	89.57
Price / Cash	N/A	157.90	50.54	59.64
Price / Book	1.85	7.88	10.28	6.07
Net Income	-$18.63M	$23.86M	$3.60B	$331.99M
7 Day Performance	23.26%	-3.82%	-1.27%	-0.63%
1 Month Performance	3.06%	-2.61%	-0.37%	-2.00%
1 Year Performance	-79.39%	32.79%	18.30%	13.62%

Femasys Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
FEMY Femasys	1.6963 of 5 stars	$3.71 -2.1%	$106.67 +2,775.1%	-79.7%	$11.20M	$2.38M	N/A	30
SLNO Soleno Therapeutics	N/A	$53.01 flat	$76.67 +44.6%	N/A	$2.76B	$285.01M	29.95	30
BDMD Baird Medical Investment	1.4547 of 5 stars	$1.09 +0.9%	N/A	-52.6%	$44.67M	$22.54M	N/A	N/A	Positive News Short Interest Decrease
IINN Inspira Technologies OXY B.H.N.	0.0131 of 5 stars	$1.19 -6.3%	N/A	-38.1%	$42.78M	$289K	N/A	20	High Trading Volume
QTI QT Imaging	0.8285 of 5 stars	$3.09 -5.5%	N/A	+38.5%	$42.55M	$18.92M	N/A	N/A	High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:FEMY) was last updated on 7/25/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Femasys (FEMY) Competitors

FEMY vs. SLNO, BDMD, IINN, QTI, and QTEX

How does Femasys compare to Soleno Therapeutics?

Summary

How does Femasys compare to Baird Medical Investment?

Summary

How does Femasys compare to Inspira Technologies OXY B.H.N.?

Summary

How does Femasys compare to QT Imaging?

Summary

How does Femasys compare to Inspira Technologies OXY B.H.N.?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FEMY vs. The Competition

Femasys Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Femasys (FEMY) Competitors

FEMY vs. SLNO, BDMD, IINN, QTI, and QTEX

How does Femasys compare to Soleno Therapeutics?

Which has better valuation and earnings, SLNO or FEMY?

Does the media refer more to SLNO or FEMY?

Do institutionals and insiders hold more shares of SLNO or FEMY?

Is SLNO or FEMY more profitable?

Do analysts prefer SLNO or FEMY?

Which has more risk and volatility, SLNO or FEMY?

Summary

How does Femasys compare to Baird Medical Investment?

Which has higher earnings & valuation, FEMY or BDMD?

Does the media refer more to FEMY or BDMD?

Do analysts prefer FEMY or BDMD?

Is FEMY or BDMD more profitable?

Which has more risk & volatility, FEMY or BDMD?

Do insiders and institutionals hold more shares of FEMY or BDMD?

Summary

How does Femasys compare to Inspira Technologies OXY B.H.N.?

Is FEMY or IINN more profitable?

Do insiders & institutionals hold more shares of FEMY or IINN?

Which has stronger earnings and valuation, FEMY or IINN?

Do analysts prefer FEMY or IINN?

Does the media prefer FEMY or IINN?

Which has more volatility & risk, FEMY or IINN?

Summary

How does Femasys compare to QT Imaging?

Is FEMY or QTI more profitable?

Which has more volatility & risk, FEMY or QTI?

Do insiders and institutionals hold more shares of FEMY or QTI?

Which has preferable earnings & valuation, FEMY or QTI?

Do analysts recommend FEMY or QTI?

Does the media prefer FEMY or QTI?

Summary

How does Femasys compare to Inspira Technologies OXY B.H.N.?

Do institutionals and insiders believe in QTEX or FEMY?

Does the media favor QTEX or FEMY?

Which has stronger earnings & valuation, QTEX or FEMY?

Do analysts rate QTEX or FEMY?

Is QTEX or FEMY more profitable?

Which has more risk and volatility, QTEX or FEMY?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FEMY vs. The Competition

Femasys Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools